Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone augmentation in postmenopausal TRD
NCT02900092Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ganaxolone in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoint: Montgomery-Asberg Depression Rating Scale at Week 8. Started Nov 2016; status: completed.
02
Drugs
ganaxolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02900092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900092.